Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.

Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors / G. Mantovani, D. Treppiedi, E. Giardino, R. Catalano, F. Mangili, P. Vercesi, M. Arosio, A. Spada, E. Peverelli. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - 26:2(2019 Feb 01), pp. R95-R108. [10.1530/ERC-18-0442]

Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors

G. Mantovani
Primo
;
D. Treppiedi
Secondo
;
E. Giardino;R. Catalano;F. Mangili;M. Arosio;A. Spada
Penultimo
;
E. Peverelli
Ultimo
2019

Abstract

Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.
filamin A; cofilin; somatostatin receptor 2; dopamine receptor type 2; pituitary tumors
Settore MED/13 - Endocrinologia
Epidemiological determinants, molecular mechanisms and clinical criteria of treatment outcome and resistance in pituitary disease syndromes
Article (author)
File in questo prodotto:
File Dimensione Formato  
Review ERC Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.6 MB
Formato Adobe PDF
1.6 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/613944
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact